Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene

British Journal of Clinical Pharmacology

Volumn 80, Issue 5, 2015, Pages 1236-1237

  Gotanda, Keisuke ^a   Tokumoto, Tomoko ^a   Hirota, Takeshi ^a   Fukae, Masato ^a   Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

ABCG2; breast cancer resistance protein; genetic polymorphism; pharmacokinetics; sulfasalazine

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FIRTECAN; GEFITINIB; IRINOTECAN; METHOTREXATE; SALAZOSULFAPYRIDINE; TOPOTECAN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTIINFECTIVE AGENT; STOP CODON; TUMOR PROTEIN;

ALLELE; AREA UNDER THE CURVE; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; GENE FREQUENCY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LETTER; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD; CELL MEMBRANE; CLINICAL TRIAL; FEMALE; GENETICS; MALE; METABOLISM; NORMAL HUMAN; STOP CODON; YOUNG ADULT;

ANTI-INFECTIVE AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; CELL MEMBRANE; CODON, NONSENSE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFASALAZINE; YOUNG ADULT;

EID: 84946496658     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12654     Document Type: Letter

References (7)

1. Das KM, Chowdhury JR, Zapp B, Fara JW,. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology 1979; 77: 280-4.
2. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA,. Breast cancer resistance protein (BCRP/ABCG2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharmacol 2006; 3: 55-61.
3. Ieiri I,. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 2012; 27: 85-105.
4. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y,. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 2008; 84: 95-103.
5. Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, Ishikawa T,. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 2006; 70: 287-96.
6. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y,. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005; 33: 94-101.
7. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, Takada Y, Oikawa Y, Inoue H, Suzuki K, Okada R, Nishiyama J, Domoto H, Watanabe S, Fujita M, Morimoto Y, Naito M, Nishio K, Hishida A, Wakai K, Asai Y, Niwa K, Kamakura K, Nonoyama S, Sakurai Y, Hosoya T, Kanai Y, Suzuki H, Hamajima N, Shinomiya N,. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 2009; 1: 5ra11.